5月14日 - ** 基因疗法制造商青鸟生物BLUE.O的股票盘前上涨50.5%，至4.98美元
** 青鸟生物称，公司董事会批准了与投资公司凯雷CG.O和SK Capital Partners修订后的合并协议
** 根据修订后的交易条款，青鸟股东可以选择获得每股5美元的现金，或原报价每股3美元的现金，外加每股6.84美元的或有价值权，该或有价值权在实现净销售里程碑后支付
** 新要约价格为 5 美元，比 BLUE 上次收盘价溢价 51
** 公司表示："修正后的要约收购价为那些希望获得更多预付现金对价而非潜在的 CVR 上升空间的股东提供了一个替代选择
** 截至最后收盘，股价累计下跌 60.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.